These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36366475)

  • 1. Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era.
    Zerbit J; Detroit M; Meyer A; Decroocq J; Deau-Fischer B; Deschamps P; Birsen R; Mondesir J; Franchi P; Miekoutima E; Guerin C; Batista R; Bouscary D; Willems L; Vignon M
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
    Noori M; Azizi S; Abbasi Varaki F; Nejadghaderi SA; Bashash D
    Int Immunopharmacol; 2022 Sep; 110():109046. PubMed ID: 35843148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study.
    Demel I; Skopal D; Šafránková E; Rozsívalová P; Jindra P; Šrámek J; Turková A; Vydra J; Labská K; Vedrová J; Čerňan M; Szotkowski T; Móciková H; Hynková L; Šušol O; Kováčová I; Belada D; Hájek R
    Ann Hematol; 2024 Mar; 103(3):981-992. PubMed ID: 38092996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
    Guven DC; Sahin TK; Akın S; Uckun FM
    Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.
    Angotzi F; Petrella M; Berno T; Binotto G; Bonetto G; Branca A; Carraro M; Cavaretta CA; Cellini A; D'Amore F; Forlani L; Gianesello I; Gurrieri C; Imbergamo S; Lessi F; Maroccia A; Mazzetto F; Pavan L; Pezone S; Piazza F; Pravato S; Ruocco V; Scapinello G; Vianello F; Zambello R; Zatta I; Zoletto S; Padoan A; Trentin L; Visentin A
    Front Oncol; 2023; 13():1212752. PubMed ID: 37427126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.
    Guo W; Zheng Y; Feng S
    Front Cell Infect Microbiol; 2023; 13():1207225. PubMed ID: 37928188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.
    Marchesi F; Salmanton-García J; Buquicchio C; Itri F; Besson C; Dávila-Valls J; Martín-Pérez S; Fianchi L; Rahimli L; Tarantini G; Grifoni FI; Sciume M; Labrador J; Cordoba R; López-García A; Fracchiolla NS; Farina F; Ammatuna E; Cingolani A; García-Bordallo D; Gräfe SK; Bilgin YM; Dargenio M; González-López TJ; Guidetti A; Lahmer T; Lavilla-Rubira E; Méndez GA; Prezioso L; Schönlein M; Van Doesum J; Wolf D; Hersby DS; Magyari F; Van Praet J; Petzer V; Tascini C; Falces-Romero I; Glenthøj A; Cornely OA; Pagano L
    J Hematol Oncol; 2023 Apr; 16(1):32. PubMed ID: 37005697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.
    Suribhatla R; Starkey T; Ionescu MC; Pagliuca A; Richter A; Lee LYW
    Br J Haematol; 2023 Jun; 201(5):813-823. PubMed ID: 37006158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation.
    Falcone M; Tiseo G; Marchetti G; Kalo J; Galfo V; Occhineri S; Almerigogna F; Matucci T; Riccardi N; Suardi LR; Rina I; Sijoni L; Caparello MC; Cassano Cassano R; Del Giudice ML; Franciosa M; Facella F; Tancredi G; Fazzi R; Galimberti S
    Leuk Lymphoma; 2024 Oct; 65(10):1474-1481. PubMed ID: 38832710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients.
    Pascale SP; Nuccorini R; Pierri T; Di Mare R; Fabio L; Lerose E; Merlino MA; Schiavo P; Amendola A; Brucoli G; Caputo MD; Chitarrelli I; Cimminiello M; Coluzzi S; Filardi NB; Matturro A; Vertone D; Poggiaspalla M; Malaspina F; Musuraca G; Coralluzzo G; Mannarella C; Musto C; Bellettieri AP; Martinelli G; Cerchione C; Pizzuti M
    Front Immunol; 2022; 13():892331. PubMed ID: 36003404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies.
    Bergamaschi C; Pagoni M; Rosati M; Angel M; Tzannou I; Vlachou M; Darmani I; Ullah A; Bear J; Devasundaram S; Burns R; Baltadakis I; Gigantes S; Dimopoulos MA; Pavlakis GN; Terpos E; Felber BK
    Front Immunol; 2022; 13():899972. PubMed ID: 35693807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies.
    Owen C; Robinson S; Christofides A; Sehn LH
    Curr Oncol; 2022 May; 29(6):3940-3949. PubMed ID: 35735424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination for SARS-CoV-2 in Hematological Patients.
    Riccardi N; Falcone M; Yahav D
    Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination.
    Callegari C; Lazzarotto D; Soravia A; Mutti M; Lauzzana P; Peghin M; Cordella S; Fanin R; Candoni A
    Eur J Haematol; 2023 Oct; 111(4):668-670. PubMed ID: 37461815
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions.
    Duminuco A; Nardo A; Orofino A; Giunta G; Conticello C; Del Fabro V; Chiarenza A; Parisi MS; Figuera A; Leotta S; Milone G; Cupri A; Cambria D; Di Raimondo F; Romano A; Palumbo GA
    Cancer; 2024 Jan; 130(1):41-50. PubMed ID: 37658645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients.
    Piñana JL; Rodríguez-Belenguer P; Caballero D; Martino R; Lopez-Corral L; Terol MJ; Vazquez L; Calabuig M; Sanz-Linares G; Marin-Jimenez F; Alonso C; Montoro J; Ferrer E; Facal A; Pascual MJ; Rodriguez-Fernandez A; Olave MT; Cascales-Hernandez A; Gago B; Hernández-Rivas JÁ; Villalon L; Corona M; Roldán-Pérez A; Ribes-Amoros J; González-Santillana C; Garcia-Sanz R; Navarro D; Serrano-López AJ; Cedillo Á; Soria-Olivas E; Sureda A; Solano C;
    Ann Hematol; 2022 Sep; 101(9):2053-2067. PubMed ID: 35780254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.
    Ustianowski A
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1517-1527. PubMed ID: 36217836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
    Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies.
    Ollila TA; Masel RH; Reagan JL; Lu S; Rogers RD; Paiva KJ; Taher R; Burguera-Couce E; Zayac AS; Yakirevich I; Niroula R; Barth P; Olszewski AJ
    Cancer; 2022 Sep; 128(18):3319-3329. PubMed ID: 35811461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.